A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

NCT01066884 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche